Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 30 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
- 25 Mar 2015 Protocol has been amended to change in drug dose and incl/excl criteria.
- 25 Mar 2015 Planned number of patients changed from 37 to 12 as reported by ClinicalTrials.gov record.